logo
Book a meeting
Allodynic Therapeutics

Allodynic Therapeutics

Pharmaceuticals, 1785 Ne 123rd St, North Miami, Florida, 33181, United States, 1-10 Employees

allodynic.com

  • twitter
  • LinkedIn

Who is ALLODYNIC THERAPEUTICS

Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migrain...

Read More

lock icon Get Full Access
map
  • 1785 Ne 123rd St, North Miami, Florida, 33181, United States Headquarters: 1785 Ne 123rd St, North Miami, Florida, 33181, United States
  • 2010 Date Founded: 2010
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 621111 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ALLODYNIC THERAPEUTICS

Allodynic Therapeutics Org Chart and Mapping

Employees
Judi Eggleston

Judi Eggleston

Office Manager

Annette Toledano

Annette Toledano

Founder and Medical Director

See Full Org Chart arrow
email-formate-icon
View Email Formats for Allodynic Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Allodynic Therapeutics

Answer: Allodynic Therapeutics's headquarters are located at 1785 Ne 123rd St, North Miami, Florida, 33181, United States

Answer: Allodynic Therapeutics's official website is https://allodynic.com

Answer: Allodynic Therapeutics's revenue is Under $1 Million

Answer: Allodynic Therapeutics's SIC: 2834

Answer: Allodynic Therapeutics's NAICS: 621111

Answer: Allodynic Therapeutics has 1-10 employees

Answer: Allodynic Therapeutics is in Pharmaceuticals

Answer: Allodynic Therapeutics contact info: Phone number: Website: https://allodynic.com

Answer: Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migraine. Both naltrexone and acetaminophen individually can simultaneously reduce physical and emotional pain, potentially enhancing treatment outcomes. Naltrexone-acetaminophen U.S. patents extend to 2037.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access